nach oben

Cancer and Metastasis Reviews

Erschienen in:

15.04.2021

MHC heterogeneity and response of metastases to immunotherapy

verfasst von: Ignacio Algarra, Federico Garrido, Angel M. Garcia-Lora

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

In recent years, immunotherapy has proven to be an effective treatment against cancer. Cytotoxic T lymphocytes perform an important role in this anti-tumor immune response, recognizing cancer cells as foreign, through the presentation of tumor antigens by MHC class I molecules. However, tumors and metastases develop escape mechanisms for evading this immunosurveillance and may lose the expression of these polymorphic molecules to become invisible to cytotoxic T lymphocytes. In other situations, they may maintain MHC class I expression and promote immunosuppression of cytotoxic T lymphocytes. Therefore, the analysis of the expression of MHC class I molecules in tumors and metastases is important to elucidate these escape mechanisms. Moreover, it is necessary to determine the molecular mechanisms involved in these alterations to reverse them and recover the expression of MHC class I molecules on tumor cells. This review discusses the role and regulation of MHC class I expression in tumor progression. We focus on altered MHC class I phenotypes present in tumors and metastases, as well as the molecular mechanisms responsible for MHC-I alterations, emphasizing the mechanisms of recovery of the MHC class I molecules expression on cancer cells. The individualized study of the HLA class I phenotype of the tumor and the metastases of each patient will allow choosing the most appropriate immunotherapy treatment based on a personalized medicine.

Gorer, P. A. (1936). The detection of antigenic differences in mouse erythrocytes by the employment of immune Sera. British Journal of Experimental Pathology, 17(1), 42–50 Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2065193/.PubMedCentral

Dausset, J. (1952). The agglutination mechanism of trypsin modified red cells. Blood, 7(8), 816–825. https://doi.org/10.1182/blood.V7.8.816.816.CrossRefPubMed

Bjorkman, P. J., & Parham, P. (1990). Structure, function, and diversity of class I major histocompatibility complex molecules. Annual Review of Biochemistry, 59, 253–288. https://doi.org/10.1146/annurev.bi.59.070190.001345.CrossRefPubMed

Le Bouteiller, P. (2017). HLA Class I chromosomal region, genes, and products: Facts and questions. Critical Reviews in Immunology, 37(2–6), 317–357. https://doi.org/10.1615/CritRevImmunol.v37.i2-6.80.CrossRefPubMed

Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013). MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. Journal of the National Cancer Institute, 105(16), 1172–1187. https://doi.org/10.1093/jnci/djt184.CrossRefPubMed

Garrido, F., & Algarra, I. (2001). MHC antigens and tumor escape from immune surveillance. In In Advances in Cancer Research (83rd ed., pp. 117–158). Academic Press. https://doi.org/10.1016/S0065-230X(01)83005-0.

Daar, A. S., Fuggle, S. V., Fabre, J. W., Ting, A., & Morris, P. J. (1984). The detailed distribution of MHC class II antigens in normal human organs. Transplantation, 38(3), 293–298. https://doi.org/10.1097/00007890-198409000-00019.CrossRefPubMed

Janeway, C. A., Bottomly, K., Horowitz, J., Kaye, J., Jones, B., & Tite, J. (1985). Modes of cell:cell communication in the immune system. Journal of Immunology, 135(2 Suppl), 739s–742s Retrieved from http://europepmc.org/abstract/MED/3159798.

Arnold, P. Y., La Gruta, N. L., Miller, T., Vignali, K. M., Adams, P. S., Woodland, D. L., & Vignali, D. A. A. (2002). The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. Journal of Immunology, 169(2), 739–749. https://doi.org/10.4049/jimmunol.169.2.739.CrossRef

10.

Madsen, L., Labrecque, N., Engberg, J., Dierich, A., Svejgaard, A., Benoist, C., Mathis, D., & Fugger, L. (1999). Mice lacking all conventional MHC class II genes. Proceedings of the National Academy of Sciences of the United States of America, 96(18), 10338–10343. https://doi.org/10.1073/pnas.96.18.10338.CrossRefPubMedPubMedCentral

11.

Thibodeau, J., Bourgeois-Daigneault, M.-C., & Lapointe, R. (2012). Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology, 1(6), 908–916. https://doi.org/10.4161/onci.21205.CrossRefPubMedPubMedCentral

12.

Garrido, F., Algarra, I., & García-Lora, A. M. (2010). The escape of cancer from T lymphocytes: Immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunology, Immunotherapy, 59(10), 1601–1606. https://doi.org/10.1007/s00262-010-0893-2.CrossRefPubMed

13.

Blees, A., Januliene, D., Hofmann, T., Koller, N., Schmidt, C., Trowitzsch, S., Moeller, A., & Tampé, R. (2017). Structure of the human MHC-I peptide-loading complex. Nature, 551(7681), 525–528. https://doi.org/10.1038/nature24627.CrossRefPubMed

14.

Garrido, C., Algarra, I., Maleno, I., Stefanski, J., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2010). Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunology, Immunotherapy, 59(1), 13–26. https://doi.org/10.1007/s00262-009-0716-5.CrossRefPubMed

15.

Garrido, F., & Aptsiauri, N. (2019). Cancer immune escape: MHC expression in primary tumours versus metastases. Immunology, 158(4), 255–266. https://doi.org/10.1111/imm.13114.CrossRefPubMedPubMedCentral

16.

Watson, N. F. S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006). Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. International Journal of Cancer, 118(1), 6–10. https://doi.org/10.1002/ijc.21303.CrossRefPubMed

17.

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024), 1565–1570. https://doi.org/10.1126/science.1203486.CrossRefPubMed

18.

Garrido, F., Romero, I., Aptsiauri, N., & Garcia-Lora, A. M. (2016). Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. International Journal of Cancer, 138(2), 271–280. https://doi.org/10.1002/ijc.29375.CrossRefPubMed

19.

Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2018). The transition from HLA-I positive to HLA-I negative primary tumors: The road to escape from T-cell responses. Current Opinion in Immunology, 51, 123–132. https://doi.org/10.1016/j.coi.2018.03.006.CrossRefPubMed

20.

Garrido, C., Romero, I., Berruguilla, E., Cancela, B., Algarra, I., Collado, A., García-Lora, A., & Garrido, F. (2011). Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunology, Immunotherapy, 60(9), 1257–1268. https://doi.org/10.1007/s00262-011-1027-1.CrossRefPubMed

21.

Algarra, I., Collado, A., & Garrido, F. (1997). Altered MHC class I antigens in tumors. International Journal of Clinical & Laboratory Research, 27(2), 95–102. https://doi.org/10.1007/BF02912442.CrossRef

22.

Garrido, F. (2019). HLA Class-I Expression and cancer immunotherapy. In MHC Class-I Loss and Cancer Immune Escape (pp. 79–90). Springer International Publishing. https://doi.org/10.1007/978-3-030-17864-2_3.

23.

Natali, P. G., Bigotti, A., Nicotra, M. R., Viora, M., Manfredi, D., & Ferrone, S. (1984). Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Research, 44(10), 4679–4687.PubMed

24.

Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunology Today, 18(2), 89–95. https://doi.org/10.1016/s0167-5699(96)10075-x.CrossRefPubMed

25.

Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (2000). Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Advances in Immunology, 74, 181–273. https://doi.org/10.1016/s0065-2776(08)60911-6.CrossRefPubMed

26.

Campoli, M., & Ferrone, S. (2008). HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene, 27(45), 5869–5885. https://doi.org/10.1038/onc.2008.273.CrossRefPubMedPubMedCentral

27.

Cabrera, T., Angustias Fernandez, M., Sierra, A., Garrido, A., Herruzo, A., Escobedo, A., … Garrido, F. (1996). High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 50(2), 127–134. https://doi.org/10.1016/0198-8859(96)00145-0

28.

Carretero, F. J., Del Campo, A. B., Flores-Martín, J. F., Mendez, R., García-Lopez, C., Cozar, J. M., et al. (2016). Frequent HLA class I alterations in human prostate cancer: Molecular mechanisms and clinical relevance. Cancer Immunology, Immunotherapy, 65(1), 47–59. https://doi.org/10.1007/s00262-015-1774-5.CrossRefPubMed

29.

del Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González-Aseguinolaza, G., Ruiz-Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., & Aptsiauri, N. (2014). Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. International Journal of Cancer, 134(1), 102–113. https://doi.org/10.1002/ijc.28338.CrossRefPubMed

30.

Cabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz-Cabello, F., & Garrido, F. (2003). Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens, 61(3), 211–219. https://doi.org/10.1034/j.1399-0039.2003.00020.x.CrossRefPubMed

31.

Garrido, C., Paco, L., Romero, I., Berruguilla, E., Stefansky, J., Collado, A., Algarra, I., Garrido, F., & Garcia-Lora, A. M. (2012). MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis, 33(3), 687–693. https://doi.org/10.1093/carcin/bgr318.CrossRefPubMed

32.

de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Natanov, R., Putter, H., Smit, V. T. H. B. M., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J. H., & Kuppen, P. J. K. (2010). HLA-E and HLA-G Expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. The Journal of Immunology, 185(12), 7452–7459. https://doi.org/10.4049/jimmunol.1002629.CrossRefPubMed

33.

Esteban, F., Ruiz-Cabello, F., Concha, A., Pérez-Ayala, A., Sánchez-Rozas, J. A., & Garrido, F. (1990). HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clinical & Experimental Metastasis, 8(4), 319–328. https://doi.org/10.1007/BF01810678.CrossRef

34.

Glew, S. S., Connor, M. E., Snijders, P. J. F., Stanbridge, C. M., Buckley, C. H., Walboomers, J. M. M., Meijer, C. J. L. M., & Stern, P. L. (1993). HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. European Journal of Cancer, 29(14), 1963–1970. https://doi.org/10.1016/0959-8049(93)90453-M.CrossRef

35.

Cabrera, T., Garrido, V., Concha, A., Martin, J., Esquivias, J., Oliva, M. R., Ruizcabello, F., Serrano, S., & Garrido, F. (1992). HLA molecules in basal cell carcinoma of the skin. Immunobiology, 185(5), 440–452. https://doi.org/10.1016/S0171-2985(11)80086-0.CrossRefPubMed

36.

Gutierrez, J., Ruiz-Cabello, F., López Nevot, M. A., Cabrera, T., Esquivias, J., & Garrido, F. (1990). Class II HLA antigen expression in familial Polyposis coli is related to the degree of dysplasia. Immunobiology, 180(2), 138–148. https://doi.org/10.1016/S0171-2985(11)80324-4.CrossRefPubMed

37.

Tabibzadeh, S. S., Sivarajah, A., Carpenter, D., Ohlsson-Wilhelm, B. M., & Satyaswaroop, P. G. (1990). Modulation of HLA-DR Expression in epithelial cells by interleukin 1 and estradiol-17β*. The Journal of Clinical Endocrinology & Metabolism, 71(3), 740–747. https://doi.org/10.1210/jcem-71-3-740.CrossRef

38.

Oldford, S. A., Robb, J. D., Watson, P. H., & Drover, S. (2004). HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. International Journal of Cancer, 112(3), 399–406. https://doi.org/10.1002/ijc.20441.CrossRefPubMed

39.

Ostrand-Rosenberg, S., Baskar, S., Patterson, N., & Sciences, V. K. C. of B. (1996). Expression of MHC Class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens, 47(5), 414–421. https://doi.org/10.1111/j.1399-0039.1996.tb02577.x.CrossRefPubMed

40.

Kambayashi, T., & Laufer, T. M. (2014). Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? Nature Reviews. Immunology, 14(11), 719–730. https://doi.org/10.1038/nri3754.CrossRefPubMed

41.

Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019). Biological consequences of MHC-II expression by tumor cells in cancer. Clinical Cancer Research, 25(8), 2392–2402. https://doi.org/10.1158/1078-0432.CCR-18-3200.CrossRefPubMed

42.

Hilton, D. A., & West, K. P. (1990). An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma. Cancer, 66(6), 1154–1157.CrossRef

43.

Brunner, C. A., Gokel, J. M., Riethmüller, G., & Johnson, J. P. (1991). Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis. European Journal of Cancer & Clinical Oncology, 27(4), 411–416. https://doi.org/10.1016/0277-5379(91)90374-M.CrossRef

44.

Andersen, S. N., Rognum, T. O., Lund, E., Meling, G. I., & Hauge, S. (1993). Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. British Journal of Cancer, 68(1), 80–85. https://doi.org/10.1038/bjc.1993.290.CrossRefPubMedPubMedCentral

45.

López-Nevot, M. A., Garcia, E., Romero, C., Oliva, M. R., Serrano, S., & Garrido, F. (1988). Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Experimental and Clinical Immunogenetics, 5(4), 203–212.PubMed

46.

Ting, J. P.-Y., & Trowsdale, J. (2002). Genetic control of MHC class II expression. Cell, 109(Suppl), S21–S33. https://doi.org/10.1016/s0092-8674(02)00696-7.CrossRefPubMed

47.

Garrido, F., Festenstein, H., & Schirrmacher, V. (1976). Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature, 261(5562), 705–707. https://doi.org/10.1038/261705a0.CrossRefPubMed

48.

Garrido, F., Perez, M., & Torres, M. D. (1979). Absence of four H-2d antigenic specificites in an H-2d sarcoma. Journal of Immunogenetics, 6(2), 83–86. https://doi.org/10.1111/j.1744-313x.1979.tb00333.x.CrossRefPubMed

49.

Algarra, I., Gaforio, J. J., Garrido, A., Mialdea, M. J., Pérez, M., & Garrido, F. (1991). Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis. International Journal of Cancer. Supplement, 6, 73–81. https://doi.org/10.1002/ijc.2910470716.CrossRef

50.

Ballinari, D., Pierotti, M. A., Sensi, M. L., & Parmiani, G. (1983). Lack of H-2Ld locus products on a BALB/c fibrosarcoma expressing H-2k-like alien antigens. Journal of Immunogenetics, 10(2), 115–125. https://doi.org/10.1111/j.1744-313x.1983.tb01024.x.CrossRefPubMed

51.

Rosloniec, E. F., Kuhn, M. H., Genyea, C. A., Reed, A. H., Jennings, J. J., Giraldo, A. A., et al. (1984). Aggressiveness of SJL/J lymphomas correlates with absence of H-2Ds antigens. Journal of Immunology, 132(2), 945–952.

52.

Green, W. R., Rich, R. F., & Beadling, C. (1988). Differential induction of H-2K versus H-2D class I major histocompatibility antigens by recombinant gamma interferon. Lack of Kk augmentation in a leukemia virus-induced tumor is due to a cis-dominant effect. The Journal of Experimental Medicine, 167(5), 1616–1624. https://doi.org/10.1084/jem.167.5.1616.CrossRefPubMed

53.

Wallich, R., Bulbuc, N., Hämmerling, G. J., Katzav, S., Segal, S., & Feldman, M. (1985). Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature, 315(6017), 301–305. https://doi.org/10.1038/315301a0.CrossRefPubMed

54.

Ljunggren, H. G., & Kärre, K. (1985). Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. The Journal of Experimental Medicine, 162(6), 1745–1759. https://doi.org/10.1084/jem.162.6.1745.CrossRefPubMed

55.

Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T., & Huber, C. (2000). Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens, 56(4), 327–336. https://doi.org/10.1034/j.1399-0039.2000.560404.x.CrossRefPubMed

56.

Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T., & Huber, C. (2001). Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Research, 61(3), 1095–1099.PubMed

57.

Romero, I., Algarra, I., & Garcia-Lora, A. M. (2020). MHC Class I molecules and cancer progression: Lessons learned from preclinical mouse models BT - Cancer immunology: A translational medicine context. In Rezaei, N. (Ed.), (pp. 189–204). Springer International Publishing. https://doi.org/10.1007/978-3-030-30845-2_12

58.

Chen, L., & Flies, D. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 13(4), 227–242. https://doi.org/10.1038/nri3405.CrossRefPubMedPubMedCentral

59.

Jäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., & Knuth, A. (1996). Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. International Journal of Cancer, 66(4), 470–476.CrossRef

60.

Terabe, M., & Berzofsky, J. A. (2004). Immunoregulatory T cells in tumor immunity. Current Opinion in Immunology, 16(2), 157–162. https://doi.org/10.1016/j.coi.2004.01.010.CrossRefPubMed

61.

Rodríguez, T., Méndez, R., Del Campo, A., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz-Cabello, F. (2007). Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer, 7, 34. https://doi.org/10.1186/1471-2407-7-34.CrossRefPubMedPubMedCentral

62.

Pfeffer, C. M., & Singh, A. T. K. (2018). Apoptosis: A target for anticancer therapy. International Journal of Molecular Sciences, 19(2), 448. https://doi.org/10.3390/ijms19020448.CrossRefPubMedCentral

63.

Gajewski, T., Schreiber, H., & Fu, Y.-X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology, 14(10), 1014–1022. https://doi.org/10.1038/ni.2703.CrossRefPubMedPubMedCentral

64.

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., Rugo, H. S., Hwang, E. S., Jirström, K., West, B. L., & Coussens, L. M. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67. https://doi.org/10.1158/2159-8274.CD-10-0028.CrossRefPubMedPubMedCentral

65.

Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., De Cremoux, P., … Chouaib, S. (2013). Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell–mediated lysis. Cancer Research, 73(8), 2418–2427. https://doi.org/10.1158/0008-5472.CAN-12-2432

66.

Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014). WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Research, 74(9), 2510–2519. https://doi.org/10.1158/0008-5472.CAN-13-1894.CrossRefPubMedPubMedCentral

67.

Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical Cancer Research, 21(4), 687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860.CrossRefPubMed

68.

Iorgulescu, J. B., Braun, D., Oliveira, G., Keskin, D. B., & Wu, C. J. (2018). Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine, 10(1), 87. https://doi.org/10.1186/s13073-018-0598-2.CrossRefPubMed

69.

Kang, J. K., Yoon, S. J., Kim, N. K., & Heo, D. S. (2000). The expression of MHC class I, TAP1/2, and LMP2/7 gene in human gastric cancer cell lines. International Journal of Oncology, 16(6), 1159–1163. https://doi.org/10.3892/ijo.16.6.1159.CrossRefPubMed

70.

Hudson, A. W., & Ploegh, H. L. (2002). The cell biology of antigen presentation. Experimental Cell Research, 272(1), 1–7. https://doi.org/10.1006/excr.2001.5402.CrossRefPubMed

71.

Meissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., & Seliger, B. (2005). Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clinical Cancer Research, 11(7), 2552–2560. https://doi.org/10.1158/1078-0432.CCR-04-2146.CrossRefPubMed

72.

Kloor, M., Becker, C., Benner, A., Woerner, S. M., Gebert, J., Ferrone, S., & von Knebel Doeberitz, M. (2005). Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Research, 65(14), 6418–6424. https://doi.org/10.1158/0008-5472.CAN-05-0044.CrossRefPubMed

73.

Romero, J. M., Jiménez, P., Cabrera, T., Cózar, J. M., Pedrinaci, S., Tallada, M., Garrido, F., & Ruiz-Cabello, F. (2005). Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 113(4), 605–610. https://doi.org/10.1002/ijc.20499.CrossRefPubMed

74.

Garrido, F., Cabrera, T., & Aptsiauri, N. (2010). “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 127(2), 249–256. https://doi.org/10.1002/ijc.25270.CrossRefPubMed

75.

Bubeník, J. (2004). MHC class I down-regulation: Tumour escape from immune surveillance? (review). International Journal of Oncology, 25(2), 487–491.PubMed

76.

Méndez, R., Rodríguez, T., Del Campo, A., Monge, E., Maleno, I., Aptsiauri, N., … Garrido, F. (2008). Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 57(5), 719–729. https://doi.org/10.1007/s00262-007-0411-3

77.

Marincola, F. M., Shamamian, P., Simonis, T. B., Abati, A., Hackett, J., O’Dea, T., … Al, E. (1994). Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. Journal of Immunotherapy with Emphasis on Tumor Immunology, 16(1), 13–23. https://doi.org/10.1097/00002371-199407000-00002

78.

Romero, I., Martinez, M., Garrido, C., Collado, A., Algarra, I., Garrido, F., & Garcia-Lora, A. M. (2012). The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. The Journal of Pathology, 227(3), 367–379. https://doi.org/10.1002/path.4029.CrossRefPubMed

79.

Pulido, M., Chamorro, V., Romero, I., Algarra, I., S-Montalvo, A., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2020). Restoration of MHC-I on tumor cells by Fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine. Cancers, 12(6), 1563. https://doi.org/10.3390/cancers12061563.CrossRefPubMedCentral

80.

Tseng, J. E., Kemp, B. L., Khuri, F. R., Kurie, J. M., Lee, J. S., Zhou, X., Liu, D., Hong, W. K., & Mao, L. (1999). Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Research, 59(19), 4798–4803.PubMed

81.

Campiglio, M., Pekarsky, Y., Menard, S., Tagliabue, E., Pilotti, S., & Croce, C. M. (1999). FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Research, 59(16), 3866–3869.PubMed

82.

Fouts, R. L., Sandusky, G. E., Zhang, S., Eckert, G. J., Koch, M. O., Ulbright, T. M., Eble, J. N., & Cheng, L. (2003). Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer, 97(6), 1447–1452. https://doi.org/10.1002/cncr.11201.CrossRefPubMed

83.

Verri, C., Roz, L., Conte, D., Liloglou, T., Livio, A., Vesin, A., … Sozzi, G. (2009). Fragile histidine triad gene inactivation in lung cancer: The European Early Lung Cancer project. American Journal of Respiratory and Critical Care Medicine, 179(5), 396–401. https://doi.org/10.1164/rccm.200807-1153OC

84.

Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001). Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment. International Journal of Cancer, 94(2), 243–251. https://doi.org/10.1002/ijc.1452.CrossRefPubMed

85.

Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007). Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2’-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clinical Cancer Research, 13(11), 3333–3338. https://doi.org/10.1158/1078-0432.CCR-06-3091.CrossRefPubMed

86.

Maleno, I., López-Nevot, M. A., Cabrera, T., Salinero, J., & Garrido, F. (2002). Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: High frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology, Immunotherapy, 51(7), 389–396. https://doi.org/10.1007/s00262-002-0296-0.CrossRefPubMed

87.

Garrido, M. A., Rodriguez, T., Zinchenko, S., Maleno, I., Ruiz-Cabello, F., Concha, Á., Olea, N., Garrido, F., & Aptsiauri, N. (2018). HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics, 70(10), 647–659. https://doi.org/10.1007/s00251-018-1074-2.CrossRefPubMed

88.

Benitez, R., Godelaine, D., Lopez-Nevot, M. A., Brasseur, F., Jiménez, P., Marchand, M., … Garrido, F. (1998). Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 52(6), 520–529. https://doi.org/10.1111/j.1399-0039.1998.tb03082.x

89.

Bernal, M., Ruiz-Cabello, F., Concha, A., Paschen, A., & Garrido, F. (2012). Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunology, Immunotherapy, 61(9), 1359–1371. https://doi.org/10.1007/s00262-012-1321-6.CrossRefPubMed

90.

Browning, M., Petronzelli, F., Bicknell, D., Krausa, P., Rowan, A., Tonks, S., Murray, N., Bodmer, J., & Bodmer, W. (1996). Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens, 47(5), 364–371. https://doi.org/10.1111/j.1399-0039.1996.tb02571.x.CrossRefPubMed

91.

Wang, Z., Marincola, F. M., Rivoltini, L., Parmiani, G., & Ferrone, S. (1999). Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. The Journal of Experimental Medicine, 190(2), 205–215. https://doi.org/10.1084/jem.190.2.205.CrossRefPubMedPubMedCentral

92.

Serrano, A., Brady, C. S., Jimenez, P., Duggan-Keen, M. F., Mendez, R., Stern, P., Garrido, F., & Ruiz-Cabello, F. (2000). A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics, 51(12), 1047–1052. https://doi.org/10.1007/s002510000239.CrossRefPubMed

93.

Respa, A., Bukur, J., Ferrone, S., Pawelec, G., Zhao, Y., Wang, E., Marincola, F. M., & Seliger, B. (2011). Association of IFN-γ signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clinical Cancer Research, 17(9), 2668–2678. https://doi.org/10.1158/1078-0432.CCR-10-2114.CrossRefPubMedPubMedCentral

94.

Abril, E., Real, L. M., Serrano, A., Jimenez, P., García, A., Canton, J., Trigo, I., Garrido, F., & Ruiz-Cabello, F. (1998). Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunology, Immunotherapy, 47(2), 113–120. https://doi.org/10.1007/s002620050511.CrossRefPubMed

95.

Dovhey, S. E., Ghosh, N. S., & Wright, K. L. (2000). Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Research, 60(20), 5789–5796.PubMed

96.

Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., Gutzmer, R., Utikal, J., Loquai, C., Gogas, H., Klein-Hitpass, L., Zeschnigk, M., Westendorf, A. M., Trilling, M., Horn, S., Schilling, B., Schadendorf, D., Griewank, K. G., & Paschen, A. (2017). Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nature Communications, 8, 15440. https://doi.org/10.1038/ncomms15440.CrossRefPubMedPubMedCentral

97.

Dunn, G. P., Sheehan, K. C. F., Old, L. J., & Schreiber, R. D. (2005). IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Research, 65(8), 3447–3453. https://doi.org/10.1158/0008-5472.CAN-04-4316.CrossRefPubMed

98.

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014). New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape. Current Opinion in Immunology, 27, 16–25. https://doi.org/10.1016/j.coi.2014.01.004.CrossRefPubMedPubMedCentral

99.

Takeda, K., Nakayama, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D. M., & Smyth, M. J. (2017). IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications, 8(1), 14607. https://doi.org/10.1038/ncomms14607.CrossRefPubMedPubMedCentral

100.

Carretero, R., Wang, E., Rodriguez, A. I., Reinboth, J., Ascierto, M. L., Engle, A. M., Liu, H., Camacho, F. M., Marincola, F. M., Garrido, F., & Cabrera, T. (2012). Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. International Journal of Cancer, 131(2), 387–395. https://doi.org/10.1002/ijc.26471.CrossRefPubMed

101.

Flores-Martín, J. F., Perea, F., Exposito-Ruiz, M., Carretero, F. J., Rodriguez, T., Villamediana, M., Ruiz-Cabello, F., Garrido, F., Cózar-Olmo, J. M., & Aptsiauri, N. (2019). A combination of positive tumor HLA-I and negative PD-L1 expression provides an immune rejection mechanism in bladder cancer. Annals of Surgical Oncology, 26(8), 2631–2639. https://doi.org/10.1245/s10434-019-07371-2.CrossRefPubMed

102.

Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., de Macedo, M. P., Austin-Breneman, J. L., Jiang, H., Chang, Q., Reddy, S. M., Chen, W. S., Tetzlaff, M. T., Broaddus, R. J., Davies, M. A., Gershenwald, J. E., Haydu, L., Lazar, A. J., Patel, S. P., Hwu, P., Hwu, W. J., Diab, A., Glitza, I. C., Woodman, S. E., Vence, L. M., Wistuba, I. I., Amaria, R. N., Kwong, L. N., Prieto, V., Davis, R. E., Ma, W., Overwijk, W. W., Sharpe, A. H., Hu, J., Futreal, P. A., Blando, J., Sharma, P., Allison, J. P., Chin, L., & Wargo, J. A. (2016). Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery, 6(8), 827–837. https://doi.org/10.1158/2159-8290.CD-15-1545.CrossRefPubMedPubMedCentral

103.

Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., … Hakimi, A. A. (2016). Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 17(1), 231. https://doi.org/10.1186/s13059-016-1092-z

104.

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., Watkins, T. B. K., Shafi, S., Murugaesu, N., Mitter, R., Akarca, A. U., Linares, J., Marafioti, T., Henry, J. Y., van Allen, E. M., Miao, D., Schilling, B., Schadendorf, D., Garraway, L. A., Makarov, V., Rizvi, N. A., Snyder, A., Hellmann, M. D., Merghoub, T., Wolchok, J. D., Shukla, S. A., Wu, C. J., Peggs, K. S., Chan, T. A., Hadrup, S. R., Quezada, S. A., & Swanton, C. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 351(6280), 1463–1469. https://doi.org/10.1126/science.aaf1490.CrossRefPubMedPubMedCentral

105.

Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019). Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients? American Society of Clinical Oncology Educational Book, 39, 147–164. https://doi.org/10.1200/EDBK_240837.CrossRefPubMed

106.

Milo, I., Bedora-Faure, M., Garcia, Z., Thibaut, R., Périé, L., Shakhar, G., … Bousso, P. (2018). The immune system profoundly restricts intratumor genetic heterogeneity. Science Immunology, 3(29), eaat1435. https://doi.org/10.1126/sciimmunol.aat1435

107.

Romero, I., Garrido, C., Algarra, I., Chamorro, V., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2018). MHC intratumoral heterogeneity may predict cancer progression and response to immunotherapy. Frontiers in Immunology, 9(JAN), 102. https://doi.org/10.3389/fimmu.2018.00102.CrossRefPubMedPubMedCentral

108.

Garrido, A., Pérez, M., Delgado, C., Garrido, M. L., Rojano, J., Algarra, I., & Garrido, F. (1986). Influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Experimental and Clinical Immunogenetics, 3(2), 98–110.PubMed

109.

Pérez, M., Algarra, I., Ljunggren, H. G., Caballero, A., Mialdea, M. J., Gaforio, J. J., Klein, G., Kärre, K., & Garrido, F. (1990). A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. International Journal of Cancer, 46(2), 258–261. https://doi.org/10.1002/ijc.2910460219.CrossRefPubMed

110.

Garcia-Lora, A., Martinez, M., Algarra, I., Gaforio, J. J., & Garrido, F. (2003). MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. International Journal of Cancer, 106(4), 521–527. https://doi.org/10.1002/ijc.11241.CrossRefPubMed

111.

Garcia-Lora, A., Algarra, I., Gaforio, J. J., Ruiz-Cabello, F., & Garrido, F. (2001). Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. International Journal of Cancer, 91(1), 109–119.CrossRef

112.

Swanton, C. (2012). Intratumor heterogeneity: Evolution through space and time. Cancer Research, 72(19), 4875–4882. https://doi.org/10.1158/0008-5472.CAN-12-2217.CrossRefPubMedPubMedCentral

113.

Gonzalez, H., Hagerling, C., & Werb, Z. (2018). Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes and Development, 32(19–20), 1267–1284. https://doi.org/10.1101/GAD.314617.118.CrossRefPubMedPubMedCentral

114.

Shembrey, C., Huntington, N. D., & Hollande, F. (2019). Impact of tumor and immunological heterogeneity on the anti-cancer immune response. Cancers, 11(9), 1217. https://doi.org/10.3390/cancers11091217.CrossRefPubMedCentral

115.

Romero, I., Garrido, C., Algarra, I., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2014). T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Research, 74(7), 1958–1968. https://doi.org/10.1158/0008-5472.CAN-13-2084.CrossRefPubMed

116.

Ikeda, H., Lethé, B., Lehmann, F., van Baren, N., Baurain, J. F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., & Coulie, P. G. (1997). Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6(2), 199–208. https://doi.org/10.1016/s1074-7613(00)80426-4.CrossRefPubMed

117.

Real, L. M., Jimenez, P., Cantón, J., Kirkin, A., García, A., Abril, E., et al. (1998). In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. International Journal of Cancer, 75(2), 317–323.CrossRef

118.

Real, L. M., Jimenez, P., Kirkin, A., Serrano, A., García, A., Cantón, J., Zeuthen, J., Garrido, F., & Ruiz-Cabello, F. (2001). Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunology, Immunotherapy, 49(11), 621–628. https://doi.org/10.1007/s002620000154.CrossRefPubMed

119.

Carretero, R., Romero, J. M., Ruiz-Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008). Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 60(8), 439–447. https://doi.org/10.1007/s00251-008-0303-5.CrossRefPubMed

120.

Mendez, R., Serrano, A., Jäger, E., Maleno, I., Ruiz-Cabello, F., Knuth, A., & Garrido, F. (2001). Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens, 57(6), 508–519. https://doi.org/10.1034/j.1399-0039.2001.057006508.x.CrossRefPubMed

121.

Kloor, M., Michel, S., & von Knebel Doeberitz, M. (2010). Immune evasion of microsatellite unstable colorectal cancers. International Journal of Cancer, 127(5), 1001–1010. https://doi.org/10.1002/ijc.25283.CrossRefPubMed

122.

Failing, J. J., Aubry, M. C., & Mansfield, A. S. (2020). Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 70, 215–219. https://doi.org/10.1007/s00262-020-02677-7.CrossRefPubMed

123.

McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., … Swanton, C. (2017). Allele-specific HLA loss and immune escape in lung cancer evolution. Cell, 171(6), 1259-1271.e11. https://doi.org/10.1016/j.cell.2017.10.001

124.

De Mattos-Arruda, L., Sammut, S.-J., Ross, E. M., Bashford-Rogers, R., Greenstein, E., Markus, H., … Caldas, C. (2019). The genomic and immune landscapes of lethal metastatic breast cancer. Cell Reports, 27(9), 2690-2708.e10. https://doi.org/10.1016/j.celrep.2019.04.098

125.

Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016). The urgent need to recover MHC class I in cancers for effective immunotherapy. Current Opinion in Immunology, 39, 44–51. https://doi.org/10.1016/j.coi.2015.12.007.CrossRefPubMedPubMedCentral

126.

Lin, P.-Y., Sun, L., Thibodeaux, S. R., Ludwig, S. M., Vadlamudi, R. K., Hurez, V. J., Bahar, R., Kious, M. J., Livi, C. B., Wall, S. R., Chen, L., Zhang, B., Shin, T., & Curiel, T. J. (2010). B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. Journal of Immunology, 185(5), 2747–2753. https://doi.org/10.4049/jimmunol.1000496.CrossRef

127.

Özdemir, B. C., & Dotto, G.-P. (2019). Sex hormones and anticancer immunity. Clinical Cancer Research, 25(15), 4603–4610. https://doi.org/10.1158/1078-0432.CCR-19-0137.CrossRefPubMed

128.

Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X.-S. (2019). The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex. International Journal of Cancer, 145(10), 2840–2849. https://doi.org/10.1002/ijc.32327.CrossRefPubMed

129.

Capone, I., Marchetti, P., Ascierto, P. A., Malorni, W., & Gabriele, L. (2018). Sexual dimorphism of immune responses: A new perspective in cancer immunotherapy. Frontiers in Immunology, 9, 552. https://doi.org/10.3389/fimmu.2018.00552.CrossRefPubMedPubMedCentral

130.

Fink, A. L., Engle, K., Ursin, R. L., Tang, W.-Y., & Klein, S. L. (2018). Biological sex affects vaccine efficacy and protection against influenza in mice. Proceedings of the National Academy of Sciences of the United States of America, 115(49), 12477–12482. https://doi.org/10.1073/pnas.1805268115.CrossRefPubMedPubMedCentral

131.

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., … Hodi, F. S. (2018). MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 10(450), eaar3342. https://doi.org/10.1126/scitranslmed.aar3342

132.

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., Saco, J., Homet Moreno, B., Mezzadra, R., Chmielowski, B., Ruchalski, K., Shintaku, I. P., Sanchez, P. J., Puig-Saus, C., Cherry, G., Seja, E., Kong, X., Pang, J., Berent-Maoz, B., Comin-Anduix, B., Graeber, T. G., Tumeh, P. C., Schumacher, T. N. M., Lo, R. S., & Ribas, A. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. The New England Journal of Medicine, 375(9), 819–829. https://doi.org/10.1056/nejmoa1604958.CrossRefPubMedPubMedCentral

133.

Perea, F., Sánchez-Palencia, A., Gómez-Morales, M., Bernal, M., Concha, Á., García, M. M., … Aptsiauri, N. (2018). HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape. Oncotarget, 9(3), 4120–4133. https://doi.org/10.18632/oncotarget.23469

134.

Lee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., Strbenac, D., Saw, R. P. M., Thompson, J. F., Wilmott, J. S., Scolyer, R. A., Long, G. V., Kefford, R. F., & Rizos, H. (2020). Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 11(1), 1897. https://doi.org/10.1038/s41467-020-15726-7.CrossRefPubMedPubMedCentral

135.

Paco, L., Garcia-Lora, A. M., Casares, C., Cabrera, C., Algarra, I., Collado, A., Maleno, I., Garrido, F., & Lopez-Nevot, M. A. (2007). Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. International Journal of Cancer, 121(9), 2023–2030. https://doi.org/10.1002/ijc.22925.CrossRefPubMed

136.

Bentebibel, S.-E., Hurwitz, M. E., Bernatchez, C., Haymaker, C., Hudgens, C. W., Kluger, H. M., Tetzlaff, M. T., Tagliaferri, M. A., Zalevsky, J., Hoch, U., Fanton, C., Aung, S., Hwu, P., Curti, B. D., Tannir, N. M., Sznol, M., & Diab, A. (2019). A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discovery, 9(6), 711–721. https://doi.org/10.1158/2159-8290.CD-18-1495.CrossRefPubMed

137.

Ingegnere, T., Mariotti, F. R., Pelosi, A., Quintarelli, C., De Angelis, B., Tumino, N., … Moretta, L. (2019). Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing. Frontiers in Immunology, 10, 957. https://doi.org/10.3389/fimmu.2019.00957

138.

Vacca, P., Pietra, G., Tumino, N., Munari, E., Mingari, M. C., & Moretta, L. (2020). Exploiting human NK cells in tumor therapy. Frontiers in Immunology, 10, 3013. https://doi.org/10.3389/fimmu.2019.03013.CrossRefPubMedPubMedCentral

139.

Tumino, N., Martini, S., Munari, E., Scordamaglia, F., Besi, F., Mariotti, F. R., Bogina, G., Mingari, M. C., Vacca, P., & Moretta, L. (2019). Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. International Journal of Cancer, 145(6), 1660–1668. https://doi.org/10.1002/ijc.32262.CrossRefPubMedPubMedCentral

140.

Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., … Marcenaro, E. (2017). Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. The Journal of Allergy and Clinical Immunology, 139(1), 335-346.e3. https://doi.org/10.1016/j.jaci.2016.04.025

141.

André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., … Vivier, E. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell, 175(7), 1731-1743.e13. https://doi.org/10.1016/j.cell.2018.10.014

142.

Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R., Idorn, M., Munir Ahmad, S., Ellebæk, E., Mueller, A., Fagone, P., Nicoletti, F., Libra, M., Lauss, M., Hadrup, S. R., Schmidt, H., Andersen, M. H., thor Straten, P., Nilsson, J. A., Schumacher, T. N., Seliger, B., Jönsson, G., & Svane, I. M. (2017). Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling. Cancer Research, 77(17), 4562–4566. https://doi.org/10.1158/0008-5472.CAN-16-3172.CrossRefPubMed

143.

Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., de Castro Carpeño, J., Cobo, M., López Vivanco, G., del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto Aranda, I., Viteri, S., Pereira, E., Royuela, A., Casarrubios, M., Salas Antón, C., Parra, E. R., Wistuba, I., Calvo, V., Laza-Briviesca, R., Romero, A., Massuti, B., & Cruz-Bermúdez, A. (2020). Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 21(11), 1413–1422. https://doi.org/10.1016/S1470-2045(20)30453-8.CrossRefPubMed

Titel: MHC heterogeneity and response of metastases to immunotherapy
verfasst von: Ignacio Algarra
Federico Garrido
Angel M. Garcia-Lora
Publikationsdatum: 15.04.2021
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2021
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-021-09964-4

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

MHC heterogeneity and response of metastases to immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers

Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression

Artificial intelligence—cogito, ergo sum

The role of tumor heterogeneity in immune-tumor interactions

Role of myeloid-derived suppressor cells in metastasis

Emerging roles for myeloid immune cells in bone metastasis

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie